Liu, Yuan
Pfizer (United States)
3 papers on CoChatORCID 0000-0003-2668-0350
Most cited papers
- Verified
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., et al. (2024) · Future Oncology
Advanced Breast Cancer TherapiesProtein Degradation and Inhibitors
Cited by 116
- Verified
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
Gao, Y., Liu, Y., Yang, M., Guo, X., Zhang, M., Li, H., Li, J., & Zhao, J. (2016) · Oncotarget
Liver Disease Diagnosis and TreatmentIL-33, ST2, and ILC Pathways
Cited by 79
- Verified
Research progress on nano-sensitizers for enhancing the effects of radiotherapy
Zhang, Y., Han, X., Liu, Y., Wang, S., Han, X., & Cheng, C. (2022) · Materials Advances
Radiation Therapy and DosimetryNanoplatforms for cancer theranostics
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free